β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis-Reference-Cited by-同舟云学术

β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis

Published:2017-03 Issue:3 Volume:139 Page:923-932.e8
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Kolbinger Frank,Loesche Christian,Valentin Marie-Anne,Jiang Xiaoyu,Cheng Yi,Jarvis Philip,Peters Thomas,Calonder Claudio,Bruin Gerard,Polus Florine,Aigner Birgit,Lee David M.,Bodenlenz Manfred,Sinner Frank,Pieber Thomas Rudolf,Patel Dhavalkumar D.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference43 articles.

1. Th17 pathway in human immunity: learning from genetics and therapeutic interventions;Patel;Immunity,2015

2. Structure and signalling in the IL-17 receptor family;Gaffen;Nat Rev Immunol,2009

3. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing;Gaffen;Nat Rev Immunol,2014

4. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis;Yilmaz;Arch Dermatol Res,2012

5. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin;Johansen;Br J Dermatol,2009

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study;The Journal of Dermatology;2024-08-12

2. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis;JAMA Dermatology;2024-07-31

3. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses;Arthritis & Rheumatology;2024-07

4. Cytokines in psoriasis: From pathogenesis to targeted therapy;Human Immunology;2024-07

5. Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses;JID Innovations;2024-07